# Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-to-participate-in-the-44th-annual-j-p-morgan-healthcare-con-533f0621
Ticker: FULC
Company: Fulcrum Therapeutics
Source: Fulcrum Therapeutics
Published: 2026-01-07 13:00 EST
## Summary

Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company...

## Article Body
Fulcrum Therapeutics, Inc. ® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 10:30 a.m. ET/7:30 a.m. PT.

A live webcast of the presentation will be accessible HERE or by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations . A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.

About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.

Contact: Kevin Gardner LifeSci Advisors, LLC kgardner@lifesciadvisors.com 617-283-2856
## Recent Company News
- 2026-06-01 20:05 EST — [Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-announces-discontinuation-of-pociredir-program-in-sickle-ce-a4687a0d) — Source: Fulcrum Therapeutics
- 2026-05-08 20:30 EST — [Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--af9b71b6) — Source: Fulcrum Therapeutics
- 2026-04-27 11:00 EST — [Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results--b3f1692d) — Source: Fulcrum Therapeutics
- 2026-04-27 10:55 EST — [Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-appoints-josh-lehrer-to-its-board-of-directors-6c29e5a6) — Source: Fulcrum Therapeutics
- 2026-04-20 12:00 EST — [Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-to-host-first-quarter-2026-financial-results-conference-cal-42a5e6f1) — Source: Fulcrum Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)